Prostate cancer is the second leading cause of cancer-related death in American men. Prostate Specific Antigen (PSA) has been widely used as a screening test for prostate cancer. However, due to its lack of specificity, additional serum biomarkers are needed. PSA is, in fact, highly expressed in benign prostate epithelia as well as prostate cancer. Large-scale gene expression profiling studies performed by our group and others have identified a host of markers preferentially over-expressed in prostate cancer epithelia relative to benign. Unfortunately, however, most of these biomarkers are not secreted, expressed at relatively low levels, and thus not detectable in serum. To overcome this, our group is investigating approaches to employ the body's endogenous immune response as a natural """"""""amplification strategy"""""""" to detect carcinoma. There is a growing body of literature supporting the notion that cancer produces a humoral immune response in the host. Thus, characterizing and multiplexing this antibody repertoire for the purpose of early detection of cancer may have clinical utility. Our preliminary data provides compelling evidence that prostate cancer patients produce a humoral immune response to the prostate cancer marker, alpha-methylacyl CoA racemase (AMACR). While the immune response to AMACR represents an initial starting point, we expect that defining the entire antibody repertoire produced against tumor antigens will lead to highly specific and sensitive multiplexed assays for the detection of prostate cancer. Thus, our general approach is to harness the endogenous immune system as a biological """"""""sensor"""""""" for cancer. Given this our Aims are as follows:
Specific Aim 1 : Characterize and validate the humoral immune response to AMACR in different patient cohorts.
Specific Aim 2 : Employ high-throughput phage epitope microarrays to identify candidate humoral response markers of prostate cancer.
Specific Aim 3 : Define and develop a multiplexed protein/epitope microarray to identify prostate cancer based on humoral response.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (O1))
Program Officer
Kagan, Jacob
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Schools of Medicine
Ann Arbor
United States
Zip Code
Rye, Morten Beck; Bertilsson, Helena; Andersen, Maria K et al. (2018) Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized. BMC Cancer 18:478
Piyarathna, Danthasinghe Waduge Badrajee; Rajendiran, Thekkelnaycke M; Putluri, Vasanta et al. (2018) Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. Eur Urol Focus 4:907-915
Sailer, Verena; Schiffman, Marc H; Kossai, Myriam et al. (2018) Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer 124:1008-1015
Shukla, Shipra; Cyrta, Joanna; Murphy, Devan A et al. (2017) Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell 32:792-806.e7
Lee, D; Fontugne, J; Gumpeni, N et al. (2017) Molecular alterations in prostate cancer and association with MRI features. Prostate Cancer Prostatic Dis 20:430-435
Jin, Feng; Thaiparambil, Jose; Donepudi, Sri Ramya et al. (2017) Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prev Res (Phila) 10:588-597
Huang, Franklin W; Mosquera, Juan Miguel; Garofalo, Andrea et al. (2017) Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discov 7:973-983
Pauli, Chantal; Hopkins, Benjamin D; Prandi, Davide et al. (2017) Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov 7:462-477
Pisapia, David J; Salvatore, Steven; Pauli, Chantal et al. (2017) Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO Precis Oncol 2017:
Rennert, Hanna; Eng, Kenneth; Zhang, Tuo et al. (2016) Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. NPJ Genom Med 1:

Showing the most recent 10 out of 155 publications